Autopsy report · NCT01057277

RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer

“Pharmaceutical co- re aligned their specialties- no longer will fund H\&N ca”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 4 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

howard safran

Sponsor type

University, hospital or other

Conditions

Head and Neck Cancer

Interventions

RAD001(Afinitor)

Participants

3

Sites

1

Countries

United States

Trials that died the same way

• PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
  “Pharmaceutical collaborator pulled funding.” (63% match in meaning)
• CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
  “The pharmaceutical funder pulled funding and no longer plans to develop the drug further.” (59% match in meaning)
• Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
  “Manufacturer is no longer making the drug.” (58% match in meaning)
• Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
  “No longer have funding support to complete the pharmacogenetics component.” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.